Sle pathophysiology and management
-
Upload
samirelansary -
Category
Health & Medicine
-
view
29 -
download
1
Transcript of Sle pathophysiology and management
![Page 2: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/2.jpg)
Global Critical Carehttps://www.facebook.com/groups/1451610115129555/#!/groups/1451610115129555/
Wellcome in our new group ..... Dr.SAMIR EL ANSARY
![Page 3: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/3.jpg)
Systemic LupusErythematosus (SLE)
• Definition: a chronic inflammatory systemic autoimmune disease of unknown etiology characterized by polyclonal B-cell activation and abnormal autoantibodies
• Not one disease but several clinical subsets, some mild, e.g., “skin and joint” lupus, and others more severe, with profound thrombocytopenia, thrombosis from APS (antiphospholipid syndrome), and severe renal, lung, and CNS involvement
![Page 4: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/4.jpg)
SLE Classification Criteria
1. Malar (butterfly) rash2. Discoid lesions3. Photosensitivity4. Oral ulcers5. Non-deforming arthritis (non-erosive for the most part)6. Serositis: pleuropericarditis, aseptic peritonitis7. Renal: persistent proteinuria › 0.5 g/d or ›3+ or cellular
casts
Definite SLE = 4 or more positive criteria
![Page 5: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/5.jpg)
SLE Classification Criteria
1. Neurologic disorders: seizures, psychosis2. Heme: hemolytic anemia; leukopenia,
thrombocytopenia3. Immune: anti-DNA, or anti-Sm, or APS (ACA IgG,
IgM), or lupus anticoagulant (standard) or false + RPR
4. Positive FANA (fluorescent antinuclear antibody)
Definite SLE = 4 or more positive criteria
![Page 6: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/6.jpg)
New SLICC* Revision of the ACRClassification Criteria - Clinical
1. Acute/subacute cutaneous lupus2. Chronic cutaneous lupus3. Oral/Nasal ulcers4. Nonscarring alopecia5. Inflammatory synovitis with physician-observed swelling
of two or more joints OR tender joints with morning stiffness6. Serositis
*Systemic Lupus International Collaborating Clinics (SLICC)
![Page 7: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/7.jpg)
New SLICC* Revision of the ACRClassification Criteria - Clinical
7. Renal: Urine protein/creatinine (or 24 hr urine protein) representing at
least 500 mg of protein/24 hours or red blood cell casts8. Neurologic: seizures, psychosis, mononeuritis multiplex,
myelitis, peripheral or cranial neuropathy, cerebritis (acute confusional state)
9. Hemolytic anemia10. Leukopenia (< 4000/mm3 at least once) OR
Lymphopenia (< 1000/mm3 at least once)11. Thrombocytopenia (<100,000/mm3) at least once *Systemic Lupus International Collaborating Clinics (SLICC)
![Page 8: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/8.jpg)
SLICC Revision of the ACRClassification Criteria – Immunologic
1. ANA (antinuclear antibody) above laboratory reference range
2. Anti-dsDNA above laboratory reference range (except ELISA: twice above laboratory reference range)
3. Anti-Sm (anti-Smith) antibody4. APS abs: LAC, false-positive test for syphilis,
anticardiolipin IgG, IgM, or IgA Abs, at least twice normal or medium-high titer, same for anti-B2 glycoprotein 1
5. Low complement: low C3, low C4, low CH506. Direct Coombs test in the absence of hemolytic anemia
![Page 9: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/9.jpg)
Lupus - SLICC* 17 New Classification Criteria: 4 needed
• At least 1 clinical plus at least 1 immunologic criteria (for a total of 4)
or• Lupus nephritis by biopsy as the sole clinical
criterion plus SLE autoantibodies: (+) ANA or (+) anti-dsDNA
*Systemic Lupus International Collaborating Clinics (SLICC)
![Page 10: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/10.jpg)
The Use of ANA for Screening
• Anti-nuclear antibody (ANA) is considered a screening method for diagnosis of autoimmune disorders
• Immunofluorescence ANA assay (IF) remains the gold standard for detection of ANA {position statement)
• Many laboratories perform immunoassays (such as the multiplexed immunobead assay), for the detection of ANA as it is less labor-intensive
![Page 11: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/11.jpg)
• To compare ANA detection by multiplex immunobead assay with the gold standard immunofluorescence (IF)
• Patient samples tested for both assays:• Multiplex immunobead assay (MIA) were
considered positive based on the manufacturer’s instructions
• Immunofluorescence (IF) was considered positive at a titer ≥ 1:160
![Page 12: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/12.jpg)
Methods
• Data collected prospectively on rheumatology patients tested for ANA by multiplex immunobead assay MIA
• Performance characteristics of the immuno-assay were determined using the IF results as the “gold standard”
![Page 13: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/13.jpg)
Conclusions• Patients tested negative by the MIA (bioplex) included
patients with definite ANA-associated autoimmune diseases
• These data suggest that screening with an immunoassay would result in misclassification and potential delay or missed diagnoses of certain systemic autoimmune diseases - Multiplex immunobead assay unreliable
• Immunofluorescence (IF) should remain the preferred assay for ANA testing in patients with suspicion of autoimmune disorders until platforms with sensitivities comparable to IF or better are developed. IF the preferred method – Endorsed by the American College of Rheumatology (ACR)
![Page 14: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/14.jpg)
The Genetics of SLE
![Page 15: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/15.jpg)
SLE – Genetic Susceptibility
MHC Related• HLA-DR1, 2, 3, 4• Alleles of HLA-DRB1, IRF5, and STAT4 • C2 - C4 deficiency• TNF- polymorphisms
Not MHC Related• C1q deficiency (rare but highest risk)• Chromosome 1 region 1q41-43 (PARP),
region 1q23 (FcγRIIA, FcγRIIIA)• IL-10, IL-6 and MBL polymorphisms• Chromosome 8.p23.1: reduced
expression of BLK and increased expression of C8orf13 (B cell tyrosine kinase), chromosome 16p11.22: integrin genes IGAM-ITGAX
• B cell gene BANK1• X chromosome-linked gene IRAK1
MHC = Major Histocompatibility Complex
![Page 16: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/16.jpg)
The Genetics of Lupus – A Complex Disease
Immune complex processing: C1q, C2-4, CRP,
ITGAM, FcGR2A, etc
TLR/type I, IFN pathway:STAT 1, IRAK1,
TREX1, etc
Immune signal transduction: HLA-DR, IRF5, STAT4, BANK1, PTPN22, BLK,
TNFSF4, etc
TLR = Toll-like receptorIFN = interferon
![Page 17: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/17.jpg)
Increased Interferon Alpha (IFNα) in Lupus
The signature cytokine for the disease?
![Page 18: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/18.jpg)
Is It Lupus or IFN- Side Effects?
IFN side effects Cytopenias Anemia Arthralgias/myalgias Skin rash Alopecia (+) autoantibodies Fever, malaise/flu-like
syndrome Seizures, pneumonitis,
etc
Lupus clinical features
Basically the same constellation of signs/symptoms plus (+) autoantibodies
One and the same?
![Page 19: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/19.jpg)
SLEHow Does Tissue Injury
Occur?
![Page 20: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/20.jpg)
SLESeveral Pathogenetic Mechanisms
• Immune complex-mediated damage: glomerulonephritis• Direct autoantibody-induced damage: thrombocytopenia
and hemolytic anemia• APS-induced thrombosis and pregnancy morbidity• BLyS (BAFF)-APRIL (B lymphocyte stimulators) over-
expression: IFN, TNF, IL-1, IL-6, IL-17, etc• Complement-mediated inflammation: CNS lupus (C3a),
hypoxemia, and also anti-phospholipid mediated fetal loss• Either failure of or abnormal response to normal apoptosis
![Page 21: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/21.jpg)
![Page 22: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/22.jpg)
Lupus – Complement Levels
Patients who are always hypocomplementemic regardless of clinical disease activity may have an underlying complement deficiency!
![Page 23: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/23.jpg)
Mortality in Lupus - Bimodal Peaks
Early:• Increased disease activity • Infections due to immunosuppression
Late:• Deaths the result of permanent damage: treatment side
effects, atherosclerosis with CAD and heart attacks, strokes, pulmonary, end-stage renal disease (ESRD), etc
![Page 24: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/24.jpg)
Coronary Heart Disease in LupusPremature or Accelerated Atherosclerosis
The prevalence ranges from 6 to 15% The incidence of a MI is 5 times higher in lupus
than in the general population The risk of adverse cardiovascular outcomes is
by a factor of 7 to 17 in patients with lupus Young women (between ages 35 and 44) are
significantly more likely (52-fold increased risk) to experience an MI if they have lupus
Reasons: multifactorial and not explained just by the traditional CAD risk factors
![Page 25: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/25.jpg)
Leading Causes of Death in SLE
Active lupus Infection Cardiovascular disease
![Page 26: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/26.jpg)
SLE
Therapeutic Approaches
![Page 27: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/27.jpg)
Treatment of Lupus
• Vitamin D (an immunomodulator!) • Hydroxychloroquine (HCQ) (Plaquenil®)• Corticosteroids – Minimize to the extent possible• Immunosuppressive agents (MTX, azathioprine,
mycophenolate mofetil, etc)• Targeted biologic therapies: belimumab (Benlysta®),
rituximab (Rituxan®)
• Statins? especially for APS (antiphospholipid syndrome)?*
![Page 28: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/28.jpg)
Every patient with lupus should be on vitamin D and hydroxychloroquine (HCQ)!
• A 20-ng/ml increase in the 25 (OH) D level was associated with a 21% decrease in the odds of having a high disease activity score
• There was no evidence of additional benefit of 25 (OH) D beyond a level of 40 ng/ml
![Page 29: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/29.jpg)
Hydroxychloroquine (HCQ)
• It prevents thrombotic events in lupus patients.
• HCQ is an anti-platelet agent, inhibiting aPL-induced GPIIb/IIIa expression; it does not prolong bleeding time
• It prevents lupus flare-ups and progression of disease, including lupus nephritis . It prevents diabetes in patients with RA receiving it
![Page 30: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/30.jpg)
Hydroxychloroquine (HCQ)
• It lowers glycemia and lipids (although modestly)
• It downregulates inflammation at different levels: prostaglandins, DNA Abs, T cell activation, inhibits intracellular TLR activation , inhibits IFN-a, IL-1 and IL-6 production .
![Page 31: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/31.jpg)
Elevated biomarkers in persistently aPL-positive patients;
– IL6– VEGF– IP10– sCD40L– INFα2– IL1β– TNFα– sTF – sICAM-1
Fluvastatin 40 mg daily for 3 months reduced the levels of the following biomarkers in persistently aPL-positive patients
– IL1β– VEGF– TNFα– IP10– sCD40L– sTF
Fluvastatin effects
Fluvastatin significantly and reversibly reduced the levels of biomarkers (IL1β, VEGF, TNFα, IP10, sCD40L and sTF)
![Page 32: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/32.jpg)
NSAIDS and Steroids
INCREASES CARDIOVASCULAR DAMAGE AND SHOULD BE AVOIDED
![Page 33: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/33.jpg)
New FDA-Approved Agent – Belimumab (Benlysta®)
• Anti-BLYS humanized monoclonal antibody. • Problematic indications: not for thrombocytopenia,
CNS, or renal lupus• Helpful but modest efficacy• It helps reduce steroids, prevent flares, and
maintain disease remission
![Page 34: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/34.jpg)
The FutureBiomarkers and Targeted Therapies
• Develop better biomarkers for flares and predictors of response
• Corticosteroid-free regimens• Other B cell blockers, e.g., ocrelizumab,
epratuzumab, TACI-Ig (atacicept, an anti-BLyS/April agent).
![Page 35: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/35.jpg)
The FutureBiomarkers and Targeted Therapies
Ongoing trials : • Interferon alpha (IFN) blockers, e.g.,
sifalimumab. Good promising data. Ongoing trials• Anti-C5: humanized monoclonal Ab, especially for
APS, ongoing trials.• Interferon gamma (IFNγ) blockers: for renal
lupus. Ongoing trials
![Page 36: Sle pathophysiology and management](https://reader035.fdocuments.in/reader035/viewer/2022062406/55c5cc1cbb61ebd2368b45c4/html5/thumbnails/36.jpg)
Global Critical Carehttps://www.facebook.com/groups/1451610115129555/#!/groups/1451610115129555/
Wellcome in our new group ..... Dr.SAMIR EL ANSARY